These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 36268880)
1. Construction of an Iodine-Labeled CS1001 Antibody for Targeting PD-L1 Detection and Comparison with Low-Molecular-Peptide Micro-PET Imaging. Li D; Wang F; Jiang J; Hou X; Ding J; Wang Z; Chen Y; Liu T; Yang Z; Zhu H Mol Pharm; 2022 Nov; 19(11):4382-4389. PubMed ID: 36268880 [TBL] [Abstract][Full Text] [Related]
2. Development of novel peptide-based radiotracers for detecting PD-L1 expression and guiding cancer immunotherapy. Zhu S; Liang B; Zhou Y; Chen Y; Fu J; Qiu L; Lin J Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):625-640. PubMed ID: 37878029 [TBL] [Abstract][Full Text] [Related]
4. Sensitive Positron Emission Tomography Imaging of PD-L1 Expression in Human Breast and Lung Carcinoma Xenografts Using the Radiometalated Peptide Ga-68-TRAP-WL12. Quigley NG; Steiger K; Färber SF; Richter F; Weichert W; Notni J Mol Pharm; 2024 Apr; 21(4):1827-1837. PubMed ID: 38291706 [TBL] [Abstract][Full Text] [Related]
5. Linear Peptide-Based PET Tracers for Imaging PD-L1 in Tumors. Zhang L; Zhang S; Wu J; Wang Y; Wu Y; Sun X; Wang X; Shen J; Xie L; Zhang Y; Zhang H; Hu K; Wang F; Wang R; Zhang MR Mol Pharm; 2023 Aug; 20(8):4256-4267. PubMed ID: 37368947 [TBL] [Abstract][Full Text] [Related]
6. PET Imaging of Tumor PD-L1 Expression with a Highly Specific Nonblocking Single-Domain Antibody. Lv G; Sun X; Qiu L; Sun Y; Li K; Liu Q; Zhao Q; Qin S; Lin J J Nucl Med; 2020 Jan; 61(1):117-122. PubMed ID: 31253743 [TBL] [Abstract][Full Text] [Related]
7. PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET. Lesniak WG; Chatterjee S; Gabrielson M; Lisok A; Wharram B; Pomper MG; Nimmagadda S Bioconjug Chem; 2016 Sep; 27(9):2103-10. PubMed ID: 27458027 [TBL] [Abstract][Full Text] [Related]
8. Noninvasive evaluation of PD-L1 expression using Copper 64 labeled peptide WL12 by micro-PET imaging in Chinese hamster ovary cell tumor model. Jiang J; Li D; Liu T; Xia L; Guo X; Meng X; Liu F; Wang F; Yang Z; Zhu H Bioorg Med Chem Lett; 2021 May; 40():127901. PubMed ID: 33705912 [TBL] [Abstract][Full Text] [Related]
9. A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with Qin S; Yu Y; Guan H; Yang Y; Sun F; Sun Y; Zhu J; Xing L; Yu J; Sun X Aging (Albany NY); 2021 Apr; 13(9):13006-13022. PubMed ID: 33910164 [TBL] [Abstract][Full Text] [Related]
10. First-in-Humans Evaluation of a PD-L1-Binding Peptide PET Radiotracer in Non-Small Cell Lung Cancer Patients. Zhou X; Jiang J; Yang X; Liu T; Ding J; Nimmagadda S; Pomper MG; Zhu H; Zhao J; Yang Z; Li N J Nucl Med; 2022 Apr; 63(4):536-542. PubMed ID: 34326125 [No Abstract] [Full Text] [Related]
11. Evaluation of a Radiolabeled Macrocyclic Peptide as Potential PET Imaging Probe for PD-L1. Jouini N; Cardinale J; Mindt TL ChemMedChem; 2022 Jun; 17(12):e202200091. PubMed ID: 35388635 [TBL] [Abstract][Full Text] [Related]
12. Rapid PD-L1 detection in tumors with PET using a highly specific peptide. Chatterjee S; Lesniak WG; Miller MS; Lisok A; Sikorska E; Wharram B; Kumar D; Gabrielson M; Pomper MG; Gabelli SB; Nimmagadda S Biochem Biophys Res Commun; 2017 Jan; 483(1):258-263. PubMed ID: 28025143 [TBL] [Abstract][Full Text] [Related]
13. Construction of Anti-hPD-L1 HCAb Nb6 and Huang HF; Zhu H; Li GH; Xie Q; Yang XT; Xu XX; Tian XB; Wan YK; Yang Z Bioconjug Chem; 2019 Oct; 30(10):2614-2623. PubMed ID: 31535847 [TBL] [Abstract][Full Text] [Related]
14. Multifunctional Probe Based on "Chemical Antibody-Aptamer" for Noninvasive Detection of PD-L1 Expression in Cancer. Kong S; Liu Q; Chen Y; Liang B; Zhou Y; Lin J; Xie M; Qiu L Mol Pharm; 2024 Jan; 21(1):255-266. PubMed ID: 38093483 [TBL] [Abstract][Full Text] [Related]
15. In vivo positron emission tomography imaging for PD-L1 expression in cancer using aptamer. Choi YJ; Park JY; Cho YL; Chae JR; Cho H; Kang WJ Biochem Biophys Res Commun; 2022 Sep; 620():105-112. PubMed ID: 35780578 [TBL] [Abstract][Full Text] [Related]
16. In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1. Rubins DJ; Meng X; McQuade P; Klimas M; Getty K; Lin SA; Connolly BM; O'Malley SS; Haley H; Purcell M; Gantert L; Holahan M; Lindgren J; Eklund P; Ekblad C; Frejd FY; Hostetler ED; González Trotter DE; Evelhoch JL Mol Imaging Biol; 2021 Apr; 23(2):241-249. PubMed ID: 33098025 [TBL] [Abstract][Full Text] [Related]
17. A Novel Small Cyclic Peptide-Based Liu H; Hu M; Deng J; Zhao Y; Peng D; Feng Y; Wang L; Chen Y; Qiu L Mol Pharm; 2022 Jan; 19(1):138-147. PubMed ID: 34910492 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and Preclinical Evaluation of a Robu S; Richter A; Gosmann D; Seidl C; Leung D; Hayes W; Cohen D; Morin P; Donnelly DJ; Lipovšek D; Bonacorsi SJ; Smith A; Steiger K; Aulehner C; Krackhardt AM; Weber WA J Nucl Med; 2021 Sep; 62(9):1228-1234. PubMed ID: 33517324 [TBL] [Abstract][Full Text] [Related]
20. Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression. Zhang L; Zhang S; Wu W; Wang X; Shen J; Wang D; Hu K; Zhang MR; Wang F; Wang R J Vis Exp; 2023 Feb; (192):. PubMed ID: 36806629 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]